These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma. Samimi M Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027 [TBL] [Abstract][Full Text] [Related]
9. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma. Mitteldorf C; Berisha A; Tronnier M; Pfaltz MC; Kempf W J Cutan Pathol; 2017 Sep; 44(9):740-746. PubMed ID: 28569410 [TBL] [Abstract][Full Text] [Related]
10. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. Dowlatshahi M; Huang V; Gehad AE; Jiang Y; Calarese A; Teague JE; Dorosario AA; Cheng J; Nghiem P; Schanbacher CF; Thakuria M; Schmults CD; Wang LC; Clark RA J Invest Dermatol; 2013 Jul; 133(7):1879-89. PubMed ID: 23419694 [TBL] [Abstract][Full Text] [Related]
11. Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. Giraldo NA; Nguyen P; Engle EL; Kaunitz GJ; Cottrell TR; Berry S; Green B; Soni A; Cuda JD; Stein JE; Sunshine JC; Succaria F; Xu H; Ogurtsova A; Danilova L; Church CD; Miller NJ; Fling S; Lundgren L; Ramchurren N; Yearley JH; Lipson EJ; Cheever M; Anders RA; Nghiem PT; Topalian SL; Taube JM J Immunother Cancer; 2018 Oct; 6(1):99. PubMed ID: 30285852 [TBL] [Abstract][Full Text] [Related]
12. Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma. Bénigni P; Guénolé M; Bonsang B; Marcorelles P; Schick U; Uguen A Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):17-22. PubMed ID: 31343994 [TBL] [Abstract][Full Text] [Related]